US 12,133,849 B2
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
Dragan Cicic, Brooklyn, NY (US)
Assigned to ACTINIUM PHARMACEUTICALS, INC., New York, NY (US)
Filed by Actinium Pharmaceuticals, Inc., New York, NY (US)
Filed on Nov. 2, 2023, as Appl. No. 18/500,735.
Application 18/500,735 is a continuation of application No. 17/745,045, filed on May 16, 2022, granted, now 11,844,799.
Application 17/745,045 is a continuation of application No. 16/607,168, granted, now 11,364,235, issued on Jun. 21, 2022, previously published as PCT/US2018/029607, filed on Apr. 26, 2018.
Claims priority of provisional application 62/491,803, filed on Apr. 28, 2017.
Prior Publication US 2024/0131025 A1, Apr. 25, 2024
Prior Publication US 2024/0226095 A9, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 51/10 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 51/1069 (2013.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01)] 7 Claims
 
1. A method for treating a human subject afflicted with a hematological malignancy selected from myelodysplastic syndrome and a myeloproliferative disorder consisting of combination pharmaceutical therapy, wherein the combination pharmaceutical therapy comprises:
administering venetoclax to the subject; in conjunction with
administering 225Ac-labeled HuM195 to the subject.